For research use only. Not for therapeutic Use.
Eprotirome (CAT: I006693) is a synthetic thyroid hormone receptor agonist that selectively activates thyroid hormone receptor β (TRβ) and inhibits TRα. It has been developed as a potential treatment for dyslipidemia and metabolic syndrome. Eprotirome has shown beneficial effects on lipid profiles by increasing high-density lipoprotein (HDL) cholesterol and reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels. It also has the potential to improve insulin sensitivity and promote weight loss. However, further research is needed to fully evaluate its efficacy and safety for clinical use.
| Catalog Number | I006693 |
| CAS Number | 355129-15-6 |
| Synonyms | KB-2115; KB 2115; KB2115; Eprotirome.;3-((3,5-Dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid |
| Molecular Formula | C18H17Br2NO5 |
| Purity | ≥95% |
| Target | Thyroid Hormone Receptor |
| Solubility | Soluble in DMSO, not in water |
| Storage | -20°C |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Eprotirome is a t<span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>hyroid hormone receptor beta agonist.</span></span></span></span> |
| IUPAC Name | 3-[3,5-dibromo-4-(4-hydroxy-3-propan-2-ylphenoxy)anilino]-3-oxopropanoic acid |
| InChI | InChI=1S/C18H17Br2NO5/c1-9(2)12-7-11(3-4-15(12)22)26-18-13(19)5-10(6-14(18)20)21-16(23)8-17(24)25/h3-7,9,22H,8H2,1-2H3,(H,21,23)(H,24,25) |
| InChIKey | VPCSYAVXDAUHLT-UHFFFAOYSA-N |
| SMILES | CC(C)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Br)NC(=O)CC(=O)O)Br)O |
| Reference | <br /> |
